左氧氟沙星及头孢哌酮-舒巴坦治疗社区获得性下呼吸道感染对照.docVIP

左氧氟沙星及头孢哌酮/舒巴坦治疗社区获得性下呼吸道感染对照 　【摘要】 目的 探讨左氧氟沙星和头孢哌酮/舒巴坦治疗社区获得性下呼吸道感染的疗效及费用。方法 采用前瞻开放性随机对照研究方法。选取符合社区获得性下呼吸道感染的病例180例，随机进入实验组和对照组各90例，实验组给予左氧氟沙星注射液(300mg/100ml)静脉滴注，每日1次，疗程5～14d；对照组给予头孢哌酮/舒巴坦(4g)静脉滴注，每日1次，疗程5～14d。结果 实验组和对照组痊愈率分别为74.4%和78.9%；总有效率分别为92.2%和93.3%，两组痊愈率和有效率差异无显著性(Pgt;0.05)。实验组细菌清除率和阴转率均为89.7%，对照组细菌清除率和阴转率均为90.0%，两组比较无统计学差别(Pgt;0.05)。实验组平均疗程为(8.7±2.1)d，与对照组疗程(8.2±2.3)d比较，没有统计学差别(P＞0.05)。两组不良反应发生率也无统计学意义，但医疗费用实验组(387.2±93.5)元，远低于对照组(615±172.5)元，具有统计学意义(Plt;0.05)。结论 左氧氟沙星与头孢哌酮/舒巴坦具有相同的疗效，且医疗费用低，是治疗社区获得性下呼吸道感染安全有效的药物。 【关键词】 左氧氟沙星； 头孢哌酮/舒巴坦； 社区获得性下呼吸道细菌感染 ABSTRACT Objective To investigate the efficacy and cost of levofloxacin and cefoperazone/sulbactam in the treatment of community-acquired lower respiratory tract bacterial infections. Method A total of 180 cases with community-acquired lower respiratory tract bacterial infections were studied. A prospective randomized controlled clinical trial was conducted, and 0.3g levofloxacin or 4.0g cefoperazone/sulbactam as control were given by intravenous drip once a day for 7 to 14 days. Result The clinical efficacy rate of levofloxacin and cefoperazone/sulbactam were 92.2% and 93.3%; cure rate were 74.4% and 78.9%, and bacterial clearance were 89.7% and 90.0%, respectively. The courses of treatment were (8.7±2.1)d in patients receiving levofloxacin, while (8.2±2.3)d of control group. There was no statistical difference between two groups. The cost (RMB) of levofloxacin was significantly lower than that of cefoperazone/sulbactam (387.2±93.5 vs 615±172.5, P＜0.05). Conclusion Levofloxacin therapy was as effective as cefoperazone/sulbactam in the treatment of community-acquired lower respiratory tract bacterial infections, but the cost (RMB) of levofloxacin was lower than that of cefoperazone/sulbactam. KEY WORDS Levofloxacin; Cefoperazone/sulbactam; Community-acquired lower respiratory tract bacterial infections 左氧氟沙星(levofloxacin，LVLX)是第三代氟喹诺酮类抗菌药物，具有抗菌谱广、组织渗透性好、不良反应少等特点，由于其抗菌谱覆盖下呼吸道院外感染常见病原体，对大多数革兰阳性菌和革兰阴性菌均有抗菌活性